Premium
Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion
Author(s) -
Lu Yi,
Cai Zhong,
Galson Deborah L.,
Xiao Guozhi,
Liu Yulin,
George Diane E.,
Melhem Mona F.,
Yao Zhi,
Zhang Jian
Publication year - 2006
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20464
Subject(s) - autocrine signalling , paracrine signalling , lncap , monocyte , cancer research , ccl2 , du145 , prostate cancer , growth factor , biology , cell growth , cancer cell , chemotaxis , medicine , chemokine , inflammation , cancer , immunology , receptor , genetics
BACKGROUND Monocyte chemotactic protein‐1 (MCP‐1) plays a key role in the recruitment and activation of monocytes during inflammation. Increased MCP‐1 serum levels in patients with various cancers were correlated with advanced stage. Here, we evaluated the role of MCP‐1 on prostate cancer (CaP) cell proliferation and invasion. METHODS Expression of MCP‐1 in tissue specimens was analyzed by immunohistochemical staining. MCP‐1 production was determined by ELISA in conditioned media collected from primary prostate epithelia (PrEC), LNCaP, C4‐2B, PC3 cells, and hFOB. Cell proliferation and invasion were assayed by MTS assay and invasion chambers. RESULTS All CaP cells, as well as hFOB, produced high amount of MCP‐1 compared to PrEC cells. MCP‐1 expression levels were associated with advanced pathologic stage. MCP‐1 induced proliferation and invasion of CaP cells and this was abolished partially either by CCR2 antagonist or PI3 Kinase inhibitor. CONCLUSION MCP‐1 acts as a paracrine and autocrine factor for CaP growth and invasion. Prostate © 2006 Wiley‐Liss, Inc.